Boston Scientific (NYSE:BSX) Given Outperform Rating at Raymond James Financial

Key Points

• Raymond James reiterated an Outperform rating on Boston Scientific with an $88 price target (about a 27% upside), while the street consensus is a "Moderate Buy" with an average price target of $104.36.
• Boston Scientific beat quarterly EPS ($0.80 vs. $0.78) and reported revenue up 15.9% year‑over‑year, issuing Q1 2026 guidance of $0.780–0.800 and FY2026 guidance of $3.430–3.490 EPS.
• CEO Michael F. Mahoney sold 160,901 shares for roughly $15.0M (a 10.23% cut to his position), and the company is facing potential securities class‑action filings that pose headline and legal risk.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Raymond James Financial in a report released on Monday, MarketBeat Ratings reports. They currently have a $88.00 price objective on the medical equipment provider's stock. Raymond James Financial's price target would indicate a potential upside of 27.14% from the stock's previous close.

Several other analysts have also recently commented on BSX. Evercore lowered their target price on Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. TD Cowen decreased their price target on Boston Scientific from $115.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, February 2nd. The Goldman Sachs Group lowered their price target on Boston Scientific from $98.00 to $93.00 and set a "buy" rating on the stock in a report on Friday. Wall Street Zen cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Argus raised shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $104.36.

Boston Scientific Trading Up 0.1%

Shares of NYSE:BSX opened at $69.21 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company's 50-day moving average price is $77.45 and its 200 day moving average price is $90.61. The company has a market cap of $102.86 billion, a PE ratio of 35.68, a P/E/G ratio of 1.07 and a beta of 0.69. Boston Scientific has a fifty-two week low of $67.56 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific's quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp increased its stake in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock worth $7,002,258,000 after purchasing an additional 713,379 shares in the last quarter. Synergy Asset Management LLC raised its holdings in Boston Scientific by 3,493.0% during the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider's stock worth $48,297,000 after buying an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC raised its holdings in Boston Scientific by 39.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider's stock worth $5,065,000 after buying an additional 14,700 shares during the period. Finally, Kepler Cheuvreux Suisse SA purchased a new stake in Boston Scientific during the third quarter valued at about $26,955,000. Institutional investors own 89.07% of the company's stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: HI‑PEITHO: the EKOS™ Endovascular System showed superiority vs. anticoagulation alone for intermediate‑risk pulmonary embolism in a global randomized trial presented at ACC and published in NEJM — a meaningful clinical win that can accelerate adoption and revenue upside for the PE market. HI-PEITHO trial demonstrates Boston Scientific EKOS Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
• Positive Sentiment: CHAMPION‑AF: the WATCHMAN FLX™ LAAC device met all primary and secondary safety and efficacy endpoints vs. NOACs (statistically superior bleeding profile), a late‑breaking result that supports broader first‑line use and long‑term growth in the LAAC market. CHAMPION-AF study of the WATCHMAN FLX device meets all primary and secondary endpoints
• Positive Sentiment: Analyst support: TD Cowen reaffirmed a Buy on BSX citing CHAMPION‑AF and LAAC market growth (PT $100 retained), which provides buy‑side validation for the clinical story. Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
• Neutral Sentiment: Q1 preview: analysts expect single‑digit EPS growth for fiscal Q1 2026; guidance and the actual print will determine whether the clinical wins translate into near‑term upside. Boston Scientific's Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Conference coverage: Boston Scientific presented multiple late‑breaking trials at ACC (transcript available), increasing visibility but not immediately quantifying revenue impact. Boston Scientific Presents at American College of Cardiology 75th Annual
• Negative Sentiment: Goldman Sachs cut its price target to $93, which could pressure sentiment despite the clinical news — analyst revisions can influence near‑term flows. The Goldman Sachs Group Cuts Boston Scientific Price Target to $93.00
• Negative Sentiment: Legal overhang: multiple law firms have filed or are soliciting lead‑plaintiff claims for an alleged securities class action covering July 23, 2025–Feb 3, 2026 (lead‑plaintiff deadline May 4, 2026). Class action activity creates headline risk and potential future liabilities. INVESTOR ALERT: Boston Scientific Corporation (BSX) Investors Have Opportunity to Lead Class Action Lawsuit

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.